Investigations on sunitinib-based targeted therapies have offered convincing evidence for the substantial contributions of MUC12 to renal cancer occurrence and indicate that MUC12 is a critical metastatic promoter of the RCC phenotype. This evidence concerns the gene MUC12 and renal cell adenocarcinoma.